RevMed pancreatic cancer data may create room for rivals
Revolution Medicines’ Rasonque produced a lower response rate in pancreatic cancer patients with the most common KRAS mutation than in the overall study population. News of the data pushed the company’s shares down by more than 6%. The result could leave room for competing therapies in that subgroup.
Revolution Medicines’ Rasonque was tested in pancreatic cancer patients. Among those with the most common KRAS mutation, the response rate was lower than in the overall study population. That subgroup finding is the central detail drawing attention.
After the data emerged, the company’s shares fell by more than 6%. Because the response rate was weaker in that specific patient group, competing therapies targeting the same subgroup could find an opening.
For patients with pancreatic cancer and this KRAS mutation, the result may mean rival therapies could become more relevant. Clinicians and researchers may watch subgroup data closely. Investors in oncology drugmakers could reassess expectations. How this affects treatment choices, access, or outcomes remains uncertain.